DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,815 INR | +0.27% |
|
-1.75% | +0.29% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 280B 3.36B | Sales 2025 * | 300B 3.61B | Capitalization | 966B 11.6B |
|---|---|---|---|---|---|
| Net income 2024 | 55.78B 670M | Net income 2025 * | 55.26B 664M | EV / Sales 2024 | 3.43 x |
| Net cash position 2024 | 64.59B 776M | Net cash position 2025 * | 90.85B 1.09B | EV / Sales 2025 * | 2.91 x |
| P/E ratio 2024 |
18.4
x | P/E ratio 2025 * |
17.3
x | Employees | 25,863 |
| Yield 2024 |
0.65% | Yield 2025 * |
0.78% | Free-Float | 70.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | +0.27% | ||
| 1 week | -1.75% | ||
| Current month | -6.29% | ||
| 1 month | -2.15% | ||
| 3 months | -9.36% | ||
| 6 months | +3.75% | ||
| Current year | +0.29% |
1 week
5 710.50
5 964.65
1 month
5 710.506 420.00
Current year
5 523.456 505.50
1 year
4 385.706 505.50
3 years
3 655.006 505.50
5 years
2 352.006 505.50
10 years
1 888.006 505.50
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 18-04-01 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 20-11-01 |
| Chairman | 56 | 93-01-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 86-04-07 |
| Chairman | 56 | 93-01-17 | |
Kalpana Morparia
BRD | Director/Board Member | 74 | 07-06-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.02% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 5,799 | -0.71% | 5,589 |
| 24-05-16 | 5,840 | -0.54% | 10,580 |
| 24-05-15 | 5,872 | +0.02% | 8,065 |
| 24-05-14 | 5,871 | -0.80% | 7,041 |
| 24-05-13 | 5,919 | +0.03% | 4,011 |
Delayed Quote Bombay S.E., May 18, 2024 at 03:00 am EDT
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
2024-05-19
- Investor Meeting - Macquarie
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
5,799
INR
Average target price
6,101
INR
Spread / Average Target
+5.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.29% | 11.59B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- DRREDDY Stock
